# OnCo record camel (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/camel/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "camel", "NCT03134872" ;
  schema:name "CameL"@en ;
  schema:description "The trial that made camrelizumab a first-line lung cancer option in China, one of several domestic PD-1 antibodies to reproduce the KEYNOTE-189 result."@en ;
  schema:url <https://onco.cc/trials/camel/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03134872>, <https://doi.org/10.1016/S2213-2600(20)30365-9> ;
  onco:status "positive" ;
  onco:tag "china" ;
  onco:phase "3" ;
  schema:startDate "2017-05-12" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/camrelizumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/pemetrexed/> ;
  onco:companies <https://onco.cc/companies/hengrui/> ;
  onco:people <https://onco.cc/people/zhou-caicun/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-camel-lancet-respir-med-2021/>, <https://onco.cc/key-papers/paper-camel-j-thorac-oncol-2023-update/> .